780. Piperacillin-tazobactam versus carbapenem for treating blood stream infections due to extended spectrum beta-lactamase producing bacteria: Systematic review and meta-analysis
Session: Poster Abstract Session: Treatment of Resistant Infections - Clinical Analyses
Thursday, October 5, 2017
Room: Poster Hall CD
Background:

Infections due to extended-spectrum beta-lactamases-producing Enterobacteriaceae (ESBL-PE) pose a major public health threat due to poor outcomes and high mortality rates. Given the lack of randomized trials comparing PTZ to carbapenem in treating infections due to ESBLPE, we aimed to conduct a systematic review and meta-analysis to investigate the impact of PTZ on mortality of patients with ESBLPE bloodstream infections (BSI) compared to carbapenem.

Methods:

MEDLINE, EMBASE, Scopus, and the Cochrane library were searched electronically for studies between 1950 and January 15, 2017 that have provided data for mortality and addressed the terms “extended spectrum beta-lactamases or ESBL” and “PTZ or beta-lactam/ beta-lactamase inhibitor” and “carbapenem”. We also searched the reference sections of included studies looking for possible missed pertinent studies. Data extraction regarding study design, characteristics of the population, intervention, comparator, and outcomes was performed.

The random-effects meta-analysis was performed with the use of StatsDirect statistical software (Version 3.0.190).

Results:

Twenty nine cohort or case-control studies were included and analyzed; 12 evaluated definitive treatment and 17 studied empiric therapy. PTZ was associated with a non-statistically significant higher 30-day mortality than carbapenem [odds ratio (OR) 1.28, 95% CI 0.88–1.86] for ESBLPE BSI treatment (Figure). No statistically significant differences in mortality were found between PTZ and carbapenem administered as definitive (OR 2.46, 95% 0.93–6.54) or empirical (RR 1.12, 95% CI 0.76–1.66) treatment. A subgroup analysis that included 3 studies that reported mortality based on PTZ MIC revealed that PTZ MIC >1/4 but ≤ 4/4 is associated with a non-significantly higher mortality compared to carbapenem with OR 1.33, 95% CI 0.29-6.03. All 17 patients who had a PTZ MIC≤ 0.5/4 survived after they were treated with PTZ, but the difference with carbapenem could not be estimated.

Conclusion:

PTZ was not significantly associated with higher overall 30-day mortality compared to carbapenem in treating EBLPE BSI. It may be considered as alternative treatment, especially if PTZ MIC is ≤ 0.5/4. There is a need for randomized controlled trials to better guide clinical practice and limit the use of carbapenem.

Macintosh HD:Users:akelnhofer:Desktop:Paper_62339_abstract_69300_0.png

Maroun Sfeir, MD, MPH1,2, Gülce Askin, MPH2 and Paul Christos, Dr.PH, MS2, (1)Medicine/ Division of Infectious Disease, New York-Presbyterian Hospital/ Weill Cornell Medicine, New York, NY, (2)Healthcare Policy & Research, Weill Cornell Medicine, New York, NY

Disclosures:

M. Sfeir, None

G. Askin, None

P. Christos, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.